Center for Research and Training in the Sciences (UTSA),
Institute for Integration of Medicine & Science (UTHSA),
Translational Science Graduate Program, &
UTSA-UTHSA Joint Graduate Program in Biomedical Engineering
invite you to attend



Presents

"Rescuing Toxic Drugs Using Synthetic Proteolysis"

Bcl-xl is a well validated cancer target that is responsible for protecting many types of cancer cells from apoptosis and chemotherapy. We generated a highly potent and specific Bcl-xl syntholytic (DT2216) that can selectively induce Bcl-xl protein degradation in all the cells examined except platelets by targeting Bcl-xl to an E3 ligase barely expressed in platelets. DT2216-induced Bcl-xl degradation can selectively kill tumor cells but not normal cells and platelets. DT2216 has a favorable drug property and PK and safety profile, and a broad-spectrum anti-cancer activity in vitro and in xenograft mouse models of human cancers in vivo.



ROBERT HROMAS, MD, FACP

Dean, Joe R. and Teresa Lozano Long School of Medicine Vice President for Medical Affairs UT Health San Antonio







Friday, November 12, 2021 9:00AM - 10:00AM

For information on participating in the current monthly seminar, please head to https://www.utsa.edu/crts/strech/or scan the QR code below.



